NanoPass Technologies Ltd. (NanoPass), a developer of innovative delivery device for the enhancement of vaccines and other large molecules, has received a licensing agreement from The Infectious Disease Research Institute (IDRI) for NanoPass' proprietary MicronJet microneedle technology. This technology is intended for the intradermal delivery of products against a various diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential.
NanoPass’ single use, microneedles-based device can be used with any standard syringe to deliver liquid substance directly and consistently into the skin.
We are very excited to sign this license agreement with NanoPass, said Dr. Steven Reed, Founder and Head of IDRI’s Research and Development. NanoPass’ MicronJet technology provides targeted delivery of the vaccine to specialized cells of the immune system. We have observed a similar immunostimulating effect with our adjuvants and we look forward to evaluating the combined potential of these technologies.
IDRI also plans to apply the MicronJet technology for the administration of diagnostic skin tests.
Because microneedles are very short, they do not reach the free nerve endings of the skin that are responsible for pain sensation, and therefore most substances can be administered with microneedles with less pain. Furthermore, the microneedles are so small that they are barely visible to the naked eye, making the MicronJet far less intimidating than a conventional needle and perfect for children and needle-phobic patients.
Dr. Yotam Levin, chief executive officer of NanoPass, said: This agreement signals a new milestone for NanoPass and our MicronJet device. We are delighted to collaborate with IDRI so that this technology can be utilized in the most challenging infectious diseases that impede global health. We are excited that the MicronJet will be used to deliver innovative products targeting the needs of the poorest populations and hopefully protect many lives.